2022³â ´ëÇÑ°í°üÀýÇÐȸ °ñ´Ù°øÁõ-±Ù°¨¼ÒÁõ ½ÉÆ÷Áö¿ò : 2022-04-01 |
|
2022³â ´ëÇÑ°í°üÀýÇÐȸ °ñ´Ù°øÁõ-±Ù°¨¼ÒÁõ ½ÉÆ÷Áö¿ò : 2022-04-01 ±³À°ÀÏÀÚ : 2022-04-01 ±³À°Àå¼Ò : ¼¿ï ÀÎÅÍÄÁƼ³ÙÅ» Æĸ£³ª½º ¿ÀÅ°µåȦ ±³À°ÁÖÁ¦ : 2022³â ´ëÇÑ°í°üÀýÇÐȸ °ñ´Ù°øÁõ-±Ù°¨¼ÒÁõ ½ÉÆ÷Áö¿ò ÁÖÃÖ±â°ü : ´ëÇÑ°í°üÀýÇÐȸ ´ã´çÀÚ : ±è¼Ò¿¬ ¿¬¶ôó : 02-451-9333 À̸ÞÀÏ : khs202223@naver.com ±³À°Á¾·ù : Á¤Çü¿Ü°ú Âü¼®¿¹»óÀοø : 60¸í Èñ¸ÁÆòÁ¡ : 4Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 4 ½Ã°£ 40ºÐ ¼¼ºÎ¼ö°·á : 0¿ø ºñ°í Äڷγª ¹æ¿ªÀ» À§ÇØ ÇöÀåµî·ÏÀº ¹ÞÁö ¾Ê½À´Ï´Ù. ÇÐȸ ȨÆäÀÌÁö¸¦ Âü°íÇϽþî, »çÀüµî·Ï ºÎŹµå¸³´Ï´Ù. ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 13:00~13:10 Assessment of Bone Quantity and Quality ÀÌÁ¤¹ü(¸¶¶óÅæÁ¤Çü¿Ü°úº´¿ø) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 13:10~13:20 Role of Serologic Studies for Osteoporosis °û´ë°æ(ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 13:20~13:30 What is the Definition & Classification of ¡®Fracture Risk¡¯? ±èÁ¤ÅÃ(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 13:30~13:40 The Clinical Role of FRAX À̼±Çü(¿ï»êÀÇ´ë) Åä·Ð 04-01 ¿ÀÅ°µåȦ 13:40~14:00 Panel Discussion ´Ù°»ç(´Ù¼Ò¼Ó) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 14:00~14:10 What is the Target of Treatment & How can we Reach There? º¯¼ºÀº(Â÷ÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 14:10~14:20 Calcium & Vitamin D in a Real Life ±èÅÂÈ£(ÀüÁÖ¿¹¼öº´¿ø) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 14:20~14:30 Proposed Algorithms of Treatment in Various Clinical Guidelines À̽ÂÁØ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 14:30~14:40 How to Live Long with Hip Fracture: Single-Combined-Sequential therapy Á¶¿ì¶÷(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 14:40~14:50 Osteoporosis Treatment Strategy in the Age of COVID-19 Â÷¿ëÇÑ(À»ÁöÀÇ´ë) Åä·Ð 04-01 ¿ÀÅ°µåȦ 14:50~15:15 Panel Discussion ´Ù°»ç(´Ù¼Ò¼Ó) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 15:15~15:35 Sequential Treatment of Osteoporosis using Zoledronic Acid ¹ÚÀå¿ø(ÀÌÈÀÇ´ë) ÈÞ½Ä 04-01 ¿ÀÅ°µåȦ 15:35~15:55 () ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 15:55~16:05 Definition & Necessity of FLS Á¤È¸Á¤(¿øÁÖ¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 16:05~16:15 The Result of FLS in the Literatures ÀÌÇö¿í(¼øõÇâÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 16:15~16:25 Establishment of FLS in Korea ±è±¤±Õ(°Ç¾çÀÇ´ë) Åä·Ð 04-01 ¿ÀÅ°µåȦ 16:25~16:40 Panel Discussion ´Ù°»ç(´Ù¼Ò¼Ó) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 16:40~17:00 Initial Osteoporosis Treatment with Anabolic Agent ±èÀ̼®(ÇѾçÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 17:00~17:10 Sarcopenia: Updated Consensus in Definition and Diagnosis À¯ÁØÀÏ(°æ»óÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 17:10~17:20 Dysmobility syndrome: Updated Consensus in Definition and Diagnosis ±èâÇö(¼øõÇâÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 17:20~17:30 Non-pharmacological Management for Sarcopenia and Dysmobility Syndrome Á¶º´¿ì(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04-01 ¿ÀÅ°µåȦ 17:30~17:40 Pharmacological Management for Sarcopenia and Dysmobility Syndrome À±À翬(µ¿±¹ÀÇ´ë) Åä·Ð 04-01 ¿ÀÅ°µåȦ 17:40~18:00 Panel Discussion ´Ù°»ç(´Ù¼Ò¼Ó) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|